{"doi":"10.4103/joco.joco_251_23","title":"Comparison between the Efficacy and Tolerability of Polyvinylpyrrolidone-Iodine Eye Drops 0.6% and 1% in Adenoviral Keratoconjunctivitis: A Randomized Clinical Trial","abstract":"<jats:title>Abstract</jats:title>\n          <jats:sec>\n            <jats:title>Purpose:</jats:title>\n            <jats:p>To investigate the effect of topical Polyvinylpyrrolidone-iodine (PVP-I) 0.6% on the clinical course of adenoviral keratoconjunctivitis compared with PVP-I 1% and artificial tears.</jats:p>\n          </jats:sec>\n          <jats:sec>\n            <jats:title>Methods:</jats:title>\n            <jats:p>We prospectively enrolled all patients over 18 years of age with a polymerase chain reaction (PCR)-confirmed diagnosis of adenoviral keratoconjunctivitis who presented to the hospital between November 2022 and June 2023. Patients were randomized into 3 groups: artificial tears (control), PVP-I 1%, and PVP-I 0.6% eye drops, 4 times daily for 5 days. Clinical signs at presentation and at 6 follow-up visits during the 1<jats:sup>st</jats:sup> 3 weeks of the acute phase were recorded. Patients were also followed up at 1 and 3 months.</jats:p>\n          </jats:sec>\n          <jats:sec>\n            <jats:title>Results:</jats:title>\n            <jats:p>Ninety-four patients completed the study, of which 30, 31, and 33 were in the control, PVP-I 1%, and PVP-I 0.6% groups, respectively. The mean age of the patients was 37.2 years (interquartile range: 25-46). The PCR result was positive in 75.6% of patients with the clinical suspicion. PVP-I, regardless of the concentration, was superior to the artificial tears in terms of time to resolution of lid swelling, discharge, and incidence of subsequent subepithelial infiltrates (<jats:italic toggle=\"yes\">P</jats:italic> &lt; 0.05). However, a concentration of 0.6% was equivalent to 1%. No significant adverse events were reported in any group.</jats:p>\n          </jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:</jats:title>\n            <jats:p>The PVP-I 0.6% topical drops are safe and well tolerated in patients with acute adenoviral keratoconjunctivitis. It can be substituted for the 1% solution as it has comparable effects in improving the clinical course and reducing subsequent complications.</jats:p>\n          </jats:sec>","journal":"Journal of Current Ophthalmology","year":2023,"id":639150,"datarank":0.20794415416798362,"base_score":1.3862943611198906,"endowment":1.3862943611198906,"self_citation_contribution":0.20794415416798362,"citation_network_contribution":0.0,"self_endowment_contribution":0.20794415416798362,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":3,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1660467,"name":"Mahdi Soleymanzadeh","orcid":null,"position":1,"is_corresponding":false},{"id":1660468,"name":"Saeed Soleiman-Meigooni","orcid":null,"position":2,"is_corresponding":false},{"id":1660469,"name":"Ali Asgari","orcid":null,"position":3,"is_corresponding":false},{"id":1660470,"name":"Mohammad Reza Etemadi","orcid":null,"position":4,"is_corresponding":false},{"id":1660471,"name":"Amir Reza Mafi","orcid":null,"position":5,"is_corresponding":false},{"id":1660472,"name":"Nader Mohammadi","orcid":null,"position":6,"is_corresponding":false},{"id":1660466,"name":"Ali Makateb","orcid":null,"position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Comparison between the Efficacy and Tolerability of Polyvinylpyrrolidone-Iodine Eye Drops 0.6% and 1% in Adenoviral Keratoconjunctivitis: A Randomized Clinical Trial","abstract":"<jats:title>Abstract</jats:title>\n          <jats:sec>\n            <jats:title>Purpose:</jats:title>\n            <jats:p>To investigate the effect of topical Polyvinylpyrrolidone-iodine (PVP-I) 0.6% on the clinical course of adenoviral keratoconjunctivitis compared with PVP-I 1% and artificial tears.</jats:p>\n          </jats:sec>\n          <jats:sec>\n            <jats:title>Methods:</jats:title>\n            <jats:p>We prospectively enrolled all patients over 18 years of age with a polymerase chain reaction (PCR)-confirmed diagnosis of adenoviral keratoconjunctivitis who presented to the hospital between November 2022 and June 2023. Patients were randomized into 3 groups: artificial tears (control), PVP-I 1%, and PVP-I 0.6% eye drops, 4 times daily for 5 days. Clinical signs at presentation and at 6 follow-up visits during the 1<jats:sup>st</jats:sup> 3 weeks of the acute phase were recorded. Patients were also followed up at 1 and 3 months.</jats:p>\n          </jats:sec>\n          <jats:sec>\n            <jats:title>Results:</jats:title>\n            <jats:p>Ninety-four patients completed the study, of which 30, 31, and 33 were in the control, PVP-I 1%, and PVP-I 0.6% groups, respectively. The mean age of the patients was 37.2 years (interquartile range: 25-46). The PCR result was positive in 75.6% of patients with the clinical suspicion. PVP-I, regardless of the concentration, was superior to the artificial tears in terms of time to resolution of lid swelling, discharge, and incidence of subsequent subepithelial infiltrates (<jats:italic toggle=\"yes\">P</jats:italic> &lt; 0.05). However, a concentration of 0.6% was equivalent to 1%. No significant adverse events were reported in any group.</jats:p>\n          </jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:</jats:title>\n            <jats:p>The PVP-I 0.6% topical drops are safe and well tolerated in patients with acute adenoviral keratoconjunctivitis. It can be substituted for the 1% solution as it has comparable effects in improving the clinical course and reducing subsequent complications.</jats:p>\n          </jats:sec>","is_dataset_classified":null,"base_score":1.3862943611198906,"endowment":1.3862943611198906,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"39281394","pmcid":"PMC11392302","openalex_id":"https://openalex.org/W4402400899","authors":[],"funders":[],"total_grants":0,"fwci":0.7747,"citation_percentile":0.75377975,"influential_citations":0,"citation_trend":[{"year":2025,"count":3}],"oa_status":"gold","license":"cc-by-nc-sa","oa_locations":[{"url":"https://doi.org/10.4103/joco.joco_251_23","host_type":"journal"},{"url":"https://doi.org/10.4103/joco.joco_251_23","host_type":"publisher"},{"url":"https://journals.lww.com/10.4103/joco.joco_251_23","host_type":"publisher"},{"url":"https://pubmed.ncbi.nlm.nih.gov/39281394","host_type":"repository"},{"url":"https://www.ncbi.nlm.nih.gov/pmc/articles/11392302","host_type":"repository"},{"url":"https://doaj.org/article/6e163b99de71482aa3060966d64337c8","host_type":"repository"},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC11392302/pdf/JCO-35-337.pdf","host_type":"repository"},{"url":"https://europepmc.org/articles/PMC11392302","host_type":"Europe_PMC"},{"url":"https://europepmc.org/articles/PMC11392302?pdf=render","host_type":"Europe_PMC"}],"fields_of_study":["Ocular Surface and Contact Lens","Corneal Surgery and Treatments","Ocular Infections and Treatments"],"mesh_terms":[],"keywords":["Medicine","Artificial tears","Tolerability","Interquartile range","Keratoconjunctivitis","Randomized controlled trial","Adverse effect","Polyvinylpyrrolidone","Incidence (geometry)","Ophthalmology","Eye drop","Tears","Internal medicine","Surgery","Gastroenterology","Dermatology","Human adenovirus","Antiviral Agents","Povidone-iodine","Epidemic Keratoconjunctivitis","Subepithelial Infiltrates"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-06T22:41:09.962534Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}